Tebivudine was the first anti-hepatitis B virus drug to be classified as Safety in Pregnancy Level B at the time of marketing, and it has a better antiviral effect than lamivudine, but is slightly more expensive. With the clinical experience of using lamivudine to block mother-to-child transmission, the U.S. classification of the safety level of drugs in pregnancy, and the antiviral effect of telbivudine, many physicians looked to telbivudine for mother-to-child blockade after it was launched in 2007. The safety of telbivudine in pregnancy has always been a concern for physicians. This is because tibivudine has been found to elevate serum creatine kinase in clinical studies worldwide. Could similar adverse effects occur during pregnancy? Most of the CK elevations caused by telbivudine occur after 6-12 months of treatment, and only 4 months after the late gestation to postpartum period, so short-term treatment generally has little effect on CK and muscle. Therefore, it seems that the use of tebivudine for mother-to-child blockade of hepatitis B virus in late pregnancy is relatively safe. Ma Deming, Department of Obstetrics and Gynecology, Suzhou Fifth People’s Hospital